Quantcast
Home > Quotes > ALNY
ALNY

Alnylam Pharmaceuticals, Inc. Common Stock (ALNY) Quote & Summary Data

$71.48
*  
1.68
2.3%
Get ALNY Alerts
*Delayed - data as of Nov. 19, 2018  -  Find a broker to begin trading ALNY now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ALNY Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
135
Today's High / Low
$ 74.41 / $ 70.22
Share Volume
970,826
50 Day Avg. Daily Volume
935,991
Previous Close
$ 73.16
52 Week High / Low
$ 153.985 / $ 63.57
Market Cap
7,221,649,990
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -6.95
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.27

Intraday Chart

Shares Traded

Share Volume:
970,826
50 Day Avg. Daily Volume:
935,991

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -6.95

Trading Range

The current last sale of $71.48 is 12.44% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 74.41 $ 153.985
 Low: $ 70.22 $ 63.57

ETFs with ALNY as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
2.12% Principal Healthcare Innovators Index ETF (BTEC) -5.93 (-16.47%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a global biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. We are harnessing the RNAi pathway to develop a potential new class of innovative medicines, known as RNAi therapeutics. RNAi therapeutics are comprised of small interfering RNA, or siRNA, and function upstream of today's medicines by potently silencing messenger RNA, or mRNA, that encode for disease-causing proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases. Our research and development strategy is to target genetically validated liver-expressed genes that have been implicated in the cause or pathway of human disease.  ... More ...  


Risk Grade

Where does ALNY fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 72.72
Open Date:
Nov. 19, 2018
Close Price:
$ 71.48
Close Date:
Nov. 19, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x